Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$816.65 USD

816.65
879,559

-12.78 (-1.54%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $816.65 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.

Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update

by Zacks Equity Research

Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.

Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.

Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.

Regeneron (REGN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 3.23% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.

Sanofi (SNY) Beats on Q2 Earnings, Misses Sales, Stock Down

by Zacks Equity Research

Sanofi (SNY) beats second-quarter estimates for earnings but misses the same for sales. It raises the projected earnings growth range for 2023.

Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales

by Zacks Equity Research

Roche's (RHHBY) performance in the first half of 2023 was ordinary as COVID-19-test sales continue to decline and dent the top line.

Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QQEW

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio

by Zacks Equity Research

Alnylam's (ALNY) revenues continue to be driven by Amvuttra and Givlaari sales. Its existing collaboration agreement with Regeneron to develop RNAi-based candidates is progressing well.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

What's in Store for Thermo Fisher (TMO) in Q2 Earnings?

by Zacks Equity Research

Thermo Fisher (TMO) is likely to have generated growth in the second quarter, driven by a favorable business mix and new launches.

Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study

by Zacks Equity Research

Alnylam (ALNY) announces positive interim analysis data from the Part A of its early-stage study of ALN-APP in the treatment of early-onset Alzheimer's disease and cerebral amyloid angiopathy.

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

UnitedHealth Group (UNH) Q2 Earnings Beat, Boosts '23 EPS View

by Zacks Equity Research

UnitedHealth Group's (UNH) Q2 results benefited on the back of solid contributions from the UnitedHealthcare and Optum segments. Management presently forecasts adjusted net EPS within $24.70-$25.00 for 2023.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL

by Zacks Equity Research

Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.

The Zacks Analyst Blog Highlights Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks

by Zacks Equity Research

Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks are included in this Analyst Blog.

Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study

by Zacks Equity Research

Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.